Longeveron
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Florida, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Life Science & Technology Park 1951 NW 7...Phone Number
(844) 470-2550Website
www.longeveron.comRevenue
<$5 MillionStock Symbol
LGVNIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Longeveron
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.Explore more
Longeveron Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Longeveron your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Longeveron, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Longeveron has new funding data
Website visits: Recent activity has been detected on your website
Check if Longeveron has recently received funding, and reach out quickly before it becomes old news!
Check out if Longeveron is spiking on competitors!
Earning: See what the market has to say on Longeveron recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Longeveron
Click to see if Longeveron had a recent Job posting/layoffs
Product Launch: Get notified when Longeveron launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Longeveron
Compare insights from companies similar to Longeveron, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Longeveron is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Longeveron is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Longeveron.
Longeveron financials insights
Gather financial insights about Longeveron, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
2021
Share Placement
$20M
2024
Private Equity
$6.4M
Unspecified
$4.4M
2026
Private Equity
$15.9M
Longeveron Tech Stack
A closer look at the technologies used by Longeveron
See more technologies
Most Recent Scoops
Person-Based
Clinical Operations
Person-Based
Person-Based
Medical Research, Clinical Operations
Funding
Funding
Person-Based
Medical Research, Clinical Operations
Longeveron News & Media
Longeveron to Present at BIO International Convention 2026
Longeveron will present at BIO 2026. CEO, CFO & BD will host meetings to explore partnership opportunities for its 4 stem cell therapy developmet programs.Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic ...
Stephen Willard Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN) MIAMI, May 20, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company’s Chief Executive Officer, Stephen Willard, issued the following letter to Longeveron stockholders. Dear Fellow Stockholders, I am delighted to join Longeveron at what I beLongeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
Longeveron CEO issues 2026 Letter to Stockholders.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Longeveron
Sign Up For FreeTo access detailed company insights
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is cond... Read More
